Raymond James & Associates Chemo Centryx, Inc. Call Options Transaction History

Raymond James & Associates

  • $161 Billion
  • Q3 2024

Call Options

2 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2022

Aug 12, 2022
SELL
$15.36 - $27.51 $666,624 - $1.19 Million
-43,400 Reduced 37.16%
73,400 $222,000
Q1 2022

May 11, 2022
BUY
$22.22 - $39.12 $2.6 Million - $4.57 Million
116,800 New
116,800 $543,000

Others Institutions Holding CCXI

# of Institutions
6
Shares Held
66.3K
Call Options Held
0
Put Options Held
0
View Full List

About ChemoCentryx, Inc.

CCXI Quotes by TradingView
  • Ticker CCXI
  • Exchange NASDAQ
  • Shares Outstandng 71,919,696
  • Market Cap $3.68M
  • Description
  • ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...
More about CCXI
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email